DFE Pharma, a pharmaceutical and biopharmaceutical excipient solutions company, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome Valley, Hyderabad. This investment has enabled the company to offer specialised analytical services for Dry Powder Inhalation (DPI) dosage forms, addressing the growing demand for effective respiratory treatments.

Since its opening in September 2022, the C2F center supports global pharmaceutical companies to bring their products to market faster and more efficiently. The center's expertise lies in all phases of pharmaceutical development, initially focused on oral solid dosage (OSD), now has also extended its scope to inhaled forms.

Given the complexity of developing DPI formulations and the increasing importance of speed to market, DFE Pharma aims to ease and accelerate inhaled product development. To achieve this, the Center of Excellence now offers analytical method development, reference listed drug (RLD) characterisation, stability studies, and realistic lung deposition in-vitro techniques to enhance In-Vitro In-Vivo correlation (IVIVC). 

Additionally, with a dedicated team of inhalation specialists, the C2F center provides cutting-edge capabilities available only in few laboratories worldwide, such as anatomical throats and respiratory dissolution profiles endorsed by the FDA. These techniques shorten project timelines by minimising the need for multiple pilot pharmacokinetic studies.

"We are thrilled to announce this expansion of our C2F Center of Excellence," said Dr. Anilkumar Gandhi, Director of the C2F Center of Excellence. “With this investment in DPI expertise, we will support global customers working on inhaled products development, to bring drugs to market quickly and cost-effectively,” added Dr. Gandhi.

This investment to add analytical services for DPI dosage forms reinforces DFE Pharma’s long-term commitment to the company’s mission to provide innovative solutions to the global pharmaceutical industry.